Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

RHEUMATOLOGY IN PERSPECTIVE · RHEUMAVIEW

SJÖGREN’S · Treatments in development

New treatments for Sjögren: what stage are they at?

Research and country-specific access · Updated: 11 November 2026 (treatment evidence)

Several treatment programs are advancing, but a promising mechanism, a positive trial and an approved medicine are different things. This guide explains those stages and what the major programs are trying to change. It is a dated research map, not a list of treatments suitable for everyone.

How to read a treatment headline

Ask four questions: what does it target, what problem was studied, what results are available, and where is that exact use authorized? A drug approved for another disease is not automatically approved for Sjögren. A breakthrough designation is not marketing authorization. [R43]

“Phase III” describes a stage, not a successful result. “Completed” does not mean that results have been published. “Active” may mean that follow-up continues while recruitment is closed. A full report gives more information than a company’s announcement of success.

Back to contents ↑

Ianalumab: B-cell-directed treatmentPhase III published · regulatory review ongoing

Status: Phase III results are published; regulatory review is ongoing. A modest benefit for systemic disease activity has been shown, but a clear benefit for dryness, fatigue and pain has not been established. [R45] [R51] [R52]

Ianalumab targets BAFF-R and depletes B cells. The NEJM report included 275 and 504 randomized participants in NEPTUNUS-1 and NEPTUNUS-2. Monthly treatment improved ESSDAI, a clinician-rated measure of systemic activity, by about 1.3 and 1.0 points more than placebo. Key symptom measures, ESSPRI and SSSD, and the proportion with a large ESSDAI improvement did not differ significantly. These results help separate control of organ inflammation from how someone feels day to day. [R45]

Novartis reports FDA priority review and submissions in the United States, Europe, China and Japan. Its 10 November update still describes review as ongoing. Priority review and Breakthrough Therapy designation do not make the drug available as an approved Sjögren treatment. [R43] [R51] [R52]

A separate phase III study, THALASSA (NCT07621809), started in July 2026 for people with high symptom burden. It focuses on mouth dryness at one year. Eligibility and recruitment must be checked with the study centre. [R53]

Back to contents ↑

Dazodalibep: organs and symptoms are separate questionsSystemic benefit · separate symptom study ongoing

Status: Phase III OASIZ-301 showed a benefit for systemic activity; the separate OASIZ-303 symptom study is still ongoing. Dazodalibep remains investigational. [R46]

Dazodalibep interrupts CD40L-related immune communication. The 11 November OASIZ-301 report describes 648 randomized participants. At week 48, ESSDAI fell by 5.6 points with treatment every four weeks, 5.2 every twelve weeks and 3.8 with placebo. The extra reductions over placebo were 1.8 and 1.4 points, respectively; both were statistically significant. [R46]

The every-four-week regimen also improved reported dryness compared with placebo. This report does not establish a separate benefit for pain or fatigue. Earlier phase II symptom findings remain useful background, while OASIZ-303 is needed to answer the distinct phase III question in people selected for a high symptom burden. [R28] [R46]

Back to contents ↑

Telitacicept: China and the international programChina approval · availability depends on country

Status: Approved in China according to the manufacturer’s June 2026 disclosure; an international phase III program is ongoing. Availability and the authorized use differ by country. [R32] [R41]

Telitacicept targets BAFF and APRIL. The reported Chinese indication is for adults with active disease receiving conventional treatment. This does not mean that it is approved for Sjögren in the United States or in every other country. [R32]

UPSTREAM SjD is a separate international phase III program, NCT07404865. The registry reviewed for this chapter listed recruitment, 250 planned participants and US sites. Eligibility includes anti-SSA positivity and active disease; serious organ-threatening complications are excluded. A local centre must confirm current availability and full eligibility. [R41]

Back to contents ↑

Nipocalimab: lowering circulating IgGPhase II signal · phase III confirmation needed

Status: A phase II benefit has been reported; phase III confirmation is still needed. Nipocalimab is not an approved Sjögren treatment. [R33] [R41]

Nipocalimab blocks FcRn, a pathway that helps maintain IgG antibodies in the circulation. DAHLIAS showed a positive higher-dose result in anti-Ro-positive active disease. Lowering antibodies and improving health are related questions, but they are not identical. [R33]

The phase III DAFFODIL study, NCT06741969, is listed as active, not recruiting, with 655 actual participants in the record updated 28 August 2026. Older recruitment announcements should not override this newer status. Phase III results were not available in the retrieved record. [R41]

Back to contents ↑

Efgartigimod: why the phase III UNITY study stoppedUNITY stopped · treatment benefit not confirmed

Status: The phase III UNITY study was stopped for futility. Efgartigimod is not an established treatment for Sjögren’s disease. [R47]

Efgartigimod affects FcRn, a pathway that helps maintain circulating IgG antibodies. The small RHO trial produced an encouraging early composite-response signal without a formal hypothesis test. However, on 8 October 2026, argenx announced that an independent committee recommended stopping UNITY because it was unlikely to meet its main week-48 clinical disease-activity goal. The reason was insufficient evidence of benefit, and no new safety signal was reported. [R34] [R47]

SERENITY (NCT07760818) is a separate phase II study for defined Sjögren-related polyneuropathies, rather than for every kind of pain or tingling. The August 2026 record listed 75 planned participants and recruitment not yet started; check its current record and study centre before considering participation. [R41]

Back to contents ↑

Other immune approaches: success is not guaranteedHCQ combinations · preliminary trial results

Iscalimab targets CD40. Remibrutinib targets BTK. Their studies showed clearer signals for systemic activity than for symptoms. Another trial testing filgotinib, lanraplenib and tirabrutinib did not meet its main goal. A similar target does not make two drugs interchangeable. [R35] [R36] [R37]

HCQ combinations: a new, preliminary signal. The NECESSITY trial tested hydroxychloroquine (HCQ) with mycophenolate mofetil or leflunomide. Its ACR 2026 abstract reported a week-24 STAR composite response in about 54% and 52%, compared with 24% on placebo. A composite combines several aspects of disease; it does not mean that each symptom improved. [R48]

The clearest separation was in the group with high symptoms but low systemic activity. Results were inconclusive in the smaller group with more systemic activity and when another composite, CRESS, was used. Serious adverse events were more frequent in the HCQ–mycophenolate group. These conference findings merit discussion with a rheumatologist, but do not justify starting or changing a combination on your own. [R48]

RepurpSS studies of leflunomide–HCQ and a small low-dose IL-2 trial remain part of the wider research picture. Choice of treatment still depends on the problem being treated, individual risks and a monitoring plan. [R23] [R24] [R38]

Back to contents ↑

CAR-T and other cell therapies

Some early cell-therapy studies list Sjögren among several severe autoimmune diseases. A planned total of participants across several diagnoses is not the number of people with Sjögren already treated. A registry entry also does not establish remission or cure. [R42]

Different cellular products, conditioning regimens and target diseases have different risks. Questions include infections, immune reactions, neurological complications and long-term effects. These early studies cannot be compared fairly with established treatment by using isolated success stories from other diseases.

Back to contents ↑

Dryness treatments and gland repairCevimeline solution · FDA-approved for dry mouth

Cevimeline oral solution: approved for dry mouth. The FDA approved a liquid form of EVOXAC on 15 October 2026 for adults with Sjögren’s disease. It contains the same medicine as the capsules and may help people who have difficulty swallowing them. The manufacturer expected US availability by the end of 2026; ask a pharmacist about current supply. [R49] [R50]

This is symptom treatment, not a treatment for systemic inflammation or proof of gland regeneration. Cevimeline is unsuitable for some people, including those with uncontrolled asthma or certain eye conditions; discuss suitability and dosing with your clinician. [R54]

Local eye or mouth treatments may aim to improve moisture or surface health without changing systemic autoimmunity. Short-term secretion studies cannot prove that glands have regenerated. [R39]

Human aquaporin gene-transfer research discussed here concerns salivary damage after radiotherapy, not Sjögren disease. A result in that setting cannot be called a Sjögren cure. Gene transfer, organoids, tissue engineering and different cell products are separate approaches at different research stages. [R40] [R41]

Back to contents ↑

How to consider joining a study

Start with the study identifier and current registry, then contact the listed study centre through its official route. Confirm whether that particular site is recruiting, what the study requires and who determines eligibility. [R41] [R44]

Ask about randomization, placebo and background care; visits and travel; medication changes; rescue treatment; costs; reproductive precautions; withdrawal rights; and care after the study ends. Research may offer access to an experimental therapy, but benefit is not guaranteed. This page does not collect patient information or enroll participants.

Back to contents ↑

What do the trial numbers mean for me?

A trial can improve a clinician’s inflammation score without clearly improving dryness, fatigue or pain. Ask which outcome changed, how much more it changed than with placebo, and whether people like you were included. [R45] [R46]

For OASIZ-301, the November results report identifies 648 randomized participants. Earlier planning or registry counts describe different records and should not replace that reported randomized population. We should not invent a reason for every discrepancy. For your care, the treatment effect, risks and eligibility matter more than a headline number. [R46]

Back to contents ↑

What news would matter most next?

Look for full phase III results, the extra benefit over comparison care, effects on daily function, serious harms, longer follow-up and an actual country-specific approved indication. A headline about immune cells or antibodies is only one piece of that picture.

Your current care still matters while research advances. Eye and dental protection, symptom treatment and appropriate organ care do not have to wait for a future medicine. The next module stage examines the biological mechanisms and why promising ideas sometimes succeed and sometimes fail.

Back to contents ↑

Sources

  1. [R23] van der Heijden et al. RepurpSS-I (2020)
  2. [R24] Wong et al. RepurpSS-II (2026)
  3. [R26] Bowman et al. Ianalumab phase 2b dose-finding trial (2022)
  4. [R27] Novartis: NEPTUNUS-1/2 phase III results presented at ACR (29 October 2025)
  5. [R28] St Clair et al. Dazodalibep phase II: two populations (2024)
  6. [R29] Amgen: OASIZ 301 positive topline announcement (22 September 2026)
  7. [R32] RemeGen statutory disclosure: telitacicept Sjögren indication approval (9 June 2026)
  8. [R33] DAHLIAS: nipocalimab phase II (Lancet 2025)
  9. [R34] Peene et al. Efgartigimod RHO proof-of-concept trial (2026)
  10. [R35] Fisher et al. Iscalimab TWINSS phase 2b (2024)
  11. [R36] Dörner et al. Remibrutinib LOUiSSE phase II (2024)
  12. [R37] Price et al. Filgotinib, lanraplenib and tirabrutinib phase II (2022)
  13. [R38] He et al. Low-dose interleukin-2 randomized trial (2022)
  14. [R39] Yokoi et al. Diquafosol tear-volume pilot in Sjögren dry eye (2016)
  15. [R40] AAV2-hAQP1 gene therapy for radiation-induced xerostomia, phase I (2026)
  16. [R41] ClinicalTrials.gov: named late-stage Sjögren programs
    Additional source recordshttps://clinicaltrials.gov/study/NCT05349214https://clinicaltrials.gov/study/NCT06104124https://clinicaltrials.gov/study/NCT06245408https://clinicaltrials.gov/study/NCT05673993https://clinicaltrials.gov/study/NCT07404865https://clinicaltrials.gov/study/NCT04968912https://clinicaltrials.gov/study/NCT06741969https://clinicaltrials.gov/study/NCT05817669https://clinicaltrials.gov/study/NCT07760818https://clinicaltrials.gov/study/NCT03905525https://clinicaltrials.gov/study/NCT04035668https://clinicaltrials.gov/study/NCT03100942https://clinicaltrials.gov/study/NCT02446249
  17. [R42] ClinicalTrials.gov: early cellular studies that list Sjögren disease
    Additional source recordshttps://clinicaltrials.gov/study/NCT06828042https://clinicaltrials.gov/study/NCT06821659https://clinicaltrials.gov/study/NCT06947473
  18. [R43] Novartis: FDA Breakthrough Therapy designation for ianalumab (16 January 2026)
  19. [R44] Sjögren Foundation: find a clinical trial
  20. [R45] NEPTUNUS-1/2: randomized phase III trials, NEJM (21 October 2026)
  21. [R46] Amgen: OASIZ-301 numerical phase III results (11 November 2026)
  22. [R47] argenx: phase III UNITY stopped for futility (8 October 2026)
  23. [R48] Mariette et al. NECESSITY: ACR 2026 abstract LB15
  24. [R49] FDA: EVOXAC oral solution approval letter, NDA 221183 (15 October 2026)
  25. [R50] Cosette: EVOXAC oral solution and expected US availability (20 October 2026)
  26. [R51] Novartis Q1 2026: ianalumab priority review and regulatory submissions (28 April 2026)
  27. [R52] Novartis: NEPTUNUS extension and pending regulatory review (10 November 2026)
  28. [R53] THALASSA: phase III ianalumab for high symptom burden, NCT07621809
  29. [R54] EVOXAC prescribing information, including oral solution (October 2026)

Personal educational publication by Olga Goodman, MD. This is not a clinic portal or an emergency service. Any private expert service is separate from clinic accounts and insurance billing. Reuse requires attribution and a link to the original publication.

dr.rheumaview.com · Olga Goodman, MD

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Clinical trialsInvestigational therapiesSjögren disease